Ocelot Bio is a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics designed to significantly improve outcomes for patients with liver disease. The company’s lead clinical candidate, OCE-205, is a peptide therapeutic with a mechanism of action designed to selectively target complications of portal hypertension, such as hepatorenal syndrome with acute kidney injury (HRS-AKI), a serious and life-threatening consequence of end-stage liver disease (ESLD). Ocelot Bio plans to initiate a Phase 2 clinical trial of OCE-205 in the first half of 2022 in HRS-AKI, for which there has been no therapeutic drug innovation in over two decades. The company was founded by leading experts in peptide therapeutic development and is backed by a strong syndicate of investors including Venrock Ventures, RA Capital Management and Vivo Capital. For more information, visit www.ocelotbio.com.